Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 December 1993 | Volume 119 Issue 12 | Pages 1168-1174
Objective: To evaluate infectious morbidity associated with long-term use of venous access devices.
Design: Prospective, observational study.
Setting: Comprehensive cancer center at a university hospital.
Participants: 1431 consecutive patients with cancer requiring 1630 venous access devices for long-term use inserted between 1 June 1987 and 31 May 1989.
Measurements: Quantitative microbiologic tests to identify device-related bacteremia and fungemia, catheter tunnel infection, pocket infection in implantable port devices, and site infections; number of days the device remained in situ and time until infectious morbidity; vessel or device thrombosis and device breakage.
Results: At least one device-related infection occurred with 341 of 788 (43% [95% CI, 39% to 47%]) catheters compared with 57 of 680 (8% [CI, 6% to 10%]) completely implanted ports (P
Conclusions: The incidence of infections per device-day was 12 times greater with catheters than with ports. Patients with solid tumors were the least likely to have device-related infectious morbidity compared with those with hematologic cancers. The reasons for the difference in infectious complications is uncertain but may be attributable to type of disease, intensity of therapy, frequency with which devices are accessed, or duration of neutropenia.
Definitions of Infection
Preset criteria for the diagnosis of device-related infectious morbidity were established [9, 19].
Device-related bacteremia or fungemia was defined using the following criteria: 1) a 10-fold or greater increase in colony-forming units of organism per milliliter of blood obtained through the device compared with simultaneous peripheral blood cultures; 2) in the absence of peripheral blood cultures, more than 1000 colony-forming units of organism obtained through the device; and 3) a positive result of catheter tip culture when the device was removed specifically for suspected device-related infection in the absence of cultures as stated above.
Device-related bacteremia or fungemia was considered cured when culture results were negative at the termination of antibiotic therapy and no evidence of clinical infection occurred at least 2 weeks later.
Catheter tunnel infection was defined as induration, tenderness, and erythema beginning at least 1 cm from the catheter exit site and tracking up the catheter tract.
Port pocket infection was defined as induration, erythema, and tenderness around the port with culture-positive material aspirated from the port pocket.
Cutaneous site infection was defined as erythema, induration, or tenderness and exudate at the catheter cutaneous exit site or at the port surface needle access site.
Microbiologic Methods
Blood for culture, including quantitation, was collected into an Isolator 10 tube (Wampole Laboratories, Cranbury, New Jersey) and a 100-mm by 16-mm Vacutainer tube containing 5.95 mg of sodium polyethanol sulfonate (Becton-Dickinson Medical Systems, Rutherford, New Jersey). The Isolator tube was processed according to the manufacturer's instructions. After centrifugation, concentrated sediment from the Isolator tube was inoculated in equal portions onto two Columbia sheep blood agar plates and two chocolate agar plates, which were incubated aerobically at 37 °C in 5% CO2 in air for 5 days. Blood from the Vacutainer tube was inoculated into one bottle containing 50 mL of Columbia broth with increased cysteine and carbon dioxide (Becton-Dickinson). The bottle remained unvented during incubation. Cultures from catheter tips were taken by vortexing for 30 seconds in 30 mL of trypticase soy broth followed by inoculation of 1 drop on Columbia sheep blood plates as above with incubation for 3 days. Specimens from suspected site infections were plated on chocolate agar, MacConkey agar, and Columbia sheep blood agar with colistin and nalidixic acid.
Care of Devices
All patients with catheters required home device care. After insertion, the catheter exit site was covered with an occlusive gauze dressing until the site had healed and the Dacron cuff had engrafted (a minimum of 1 month). At this point, patients were given the option to continue to use an occlusive gauze dressing or to wear no dressing other than an adhesive bandage or a piece of tape to secure the device and prevent motion and inadvertent pulling. Each catheter lumen, when not in continual use, was flushed daily with 5 mL of heparinized saline (10 U/mL). Devices were inspected each day, and exit sites were cleaned with soap and water and then povidone-iodine solution. Catheter injection caps were changed twice each week. Patients with catheters were instructed not to swim. Patients with ports did no procedures on the device at home. Ports were flushed after each use and every 4 to 6 weeks when not in use with 5 mL of normal saline followed by 3 mL heparinized saline (100 U/mL).
Statistical Analysis
Descriptive statistical analysis consisted of paired and unpaired t-tests, analysis of variance, and chi-square analysis when indicated. For patients who had more than one device, only the first of each type was included in the analysis.
To determine whether ports are better than catheters with respect to infection and adjusting for other possible risk factors (covariates), we did a survival-type regression analysis comparison. The dependent variable was defined as the number of days until the first documented device-related infection of any kind or time of removal or last follow-up (censored observations). To avoid difficulty in interpreting results due to correlated observations for the same patient, only the first device inserted was used for the analysis, regardless of whether the patient had more than one of the same or different devices. Only patients with solid tumors, leukemia, or lymphoma or myeloma were included in the analysis of time to first infection because tumor type was likely to be a predictor of infections and because only a small proportion of patients with ports had other tumor types. Variables tested for relation to the outcome variable were device type, tumor type, age, device breakage, and clot (defined as clinical necessity to administer urokinase for an occluded device lumen or a positive venogram). Only catheter clot and breakage that occurred before the first infection or censoring time were considered and treated as time-dependent variables. The strength of the relation between infection-free time and each explanatory variable was assessed parametrically by the Wilcoxon-Gehan test statistic rather than by the log-rank test or Cox regression because the log-logistic distribution gave a better parametric fit to the data than did the Weibull distribution, and data did not follow a proportional hazards model. The Kaplan-Meier method was used to estimate time to first infection within subgroups to plot curves. The best parametric fit was obtained using the log-logistic distribution in SAS procedure LIFEREG (Statistical Analysis Systems Institute Inc., Cary, North Carolina), which allowed us to quantify the relation between risk factors and time to first infection and to give a simple predictive model. In this model, the proportion of patients in a population who have not had an infection at T days after insertion is 1/(1 + [T/A]b), where A is the baseline median duration multiplied by proportionality coefficients for relevant risk factors that significantly prolong or shorten time to infection, and b is an exponent that is inversely related to the dispersion of times to infection in the population. In all cases, a P value less than 0.05 was considered significant. All summary data are presented as mean ±SD unless otherwise specified. ARTICLE
Infectious Morbidity Associated with Long-Term Use of Venous Access Devices in Patients with Cancer
0.001). Device-related bacteremia or fungemia is the predominant infection occurring with catheters, whereas ports have a more equal distribution of pocket, site, and device-related bacteremia. The predominant organisms isolated in catheter-related bacteremia were gram-negative bacilli (55%) compared with gram-positive cocci (65.5%) in port-related bacteremia. The number of infections per 1000 device days was 2.77 (95% CI, 2.48 to 3.06) for catheters compared with 0.21 (CI, 0.16 to 0.27) for ports (P
0.001). Based on a parametric model of time to first infection, devices lasted longer in patients with solid tumors than in those with hematopoietic tumors. Ports lasted longer than catheters across all patient groups.
Semi-permanent, centrally placed venous access devices are used commonly in patients with neoplastic disease to administer chemotherapy, blood products, antibiotics, and parenteral nutrition and to obtain blood specimens for laboratory analysis. Infection is a frequent and potentially life-threatening complication of devices such as cuffed Silastic catheters [1-12]. Recent experience suggests that patients with cancer who have completely implanted port devices may be less prone to device-related infection [3, 7, 8, 13-18]. We present data from a prospective evaluation of all Hickman-type Silastic tunneled catheters (catheters) and completely implanted subcutaneous ports (ports) inserted at Memorial Sloan-Kettering Cancer Center during a 2-year period.
Methods
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
From 1 June 1987 to 31 May 1989, patients who had catheters and ports inserted at Memorial Sloan-Kettering Cancer Center were followed prospectively to identify possible device-related morbidity. Baseline demographic information was obtained from the patients' medical records and operative reports. During subsequent admissions, the chart was reviewed by the vascular access nurse clinician. Daily microbiology reports were cross-checked against the database. Any study patient not seen by a principal investigator for 3 months received a questionnaire to identify any device-related morbidity in the intervening period. Patients were contacted if questionnaires were not returned or additional information was required. Follow-up continued until the device was removed or the patient died.
Results
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
During a 2-year period beginning 1 June 1987, 1630 venous access devices were inserted in 1430 patients: 707 ports were inserted in 680 patients, and 923 catheters were inserted in 788 patients (38 patients had a catheter and a port on separate occasions). All patients were followed for a potential minimum of 500 days. Table 1 shows that the average individual number of days that devices were in situ until removal or last follow-up, without censoring for infection, is significantly longer for ports than for catheters (P
0.001). Total port days were 277 853 at last follow-up compared with 165 710 catheter days; 171 (25%) of the ports were still in situ compared with 54 (7%) of the catheters. On average, ports remained in situ 408 ± 309 days (median, 339 days), whereas catheters remained in situ 210 ± 239 days (median, 130 days).
|
At least one device-related infection occurred in 341 (43%) of the catheters compared with 57 (8%) of the ports (P
0.001) (Table 2). Both site infections and device-related bacteremia or fungemia occurred more frequently with catheters than with ports. No difference was seen in the incidence of catheter tunnel or port pocket infections. More catheters (154 [20%]) than ports (25 [3%]) were ultimately removed because of infectious morbidity (P
0.001); these figures represent slightly fewer than one half the devices that ever caused infection. There were 2.767 infections per 1000 catheter days compared with only 0.211 infections per 1000 port days (P
0.001).
|
Device-related bacteremia or fungemia was the predominant type of infection with catheters, whereas ports had a more equal distribution of pocket, site, and device-related bacteremia or fungemia (see Table 2). Without accounting for removed devices, device-related bacteremia or fungemia tended to occur later than site or tunnel tract infection. Overall, port infections occurred later than catheter infections. Port pocket infections tended to occur earlier than site infections or device-related bacteremia or fungemia; however, no statistically significant differences appeared within this device category referable to the onset of infection.
Patients with ports were older than patients with catheters, (49 ± 18 years [median, 52 years] compared with 29 ± 20 years [median, 26 years]). Differences in age were noted between patients with catheters and those with ports if they had solid tumors or leukemias (Table 3). For patients with catheters, those with lymphoma or myeloma were older than patients in all other groups except those with the acquired immunodeficiency syndrome (AIDS); those with AIDS were older than those with solid tumors and bone marrow transplant; and those with leukemia were older than those with bone marrow transplant (P < 0.05). For patients with ports, those with solid tumors were older than those with leukemia; patients with leukemia were older than those with lymphoma or myeloma (P < 0.05). Ports were inserted predominantly for treatment of adult solid tumors (breast, colon, lung), whereas catheters were used in patients with bone marrow transplants, hematologic cancers, and childhood cancers. Ports were inserted in patients with leukemia only after their acute induction and were primarily for maintenance chemotherapy. In general, patients with catheters received more aggressive chemotherapy associated with a relatively greater degree and duration of neutropenia and thrombocytopenia than did patients with ports, and their devices had to be accessed more frequently for phlebotomy or blood product transfusion. Although a wide range of leukocyte counts was found at device insertion, no statistically significant difference in counts was found for all or for specific patient categories (Table 3). The precise degree and duration of neutropenia and the frequency of device use are not available for direct comparison.
|
Microbiology
Device-related bacteremia or fungemia occurred as the initial infection with 264 catheters and 26 ports. A 10-fold difference in colony-forming units between the device and peripheral blood was found for 153 catheters and 13 ports; more than 1000 colony-forming units from the device in the absence of peripheral blood were found in 107 catheters and 12 ports; and in the remaining 4 catheters and 1 port, a positive result of a catheter tip culture was diagnostic of device-related bacteremia or fungemia. More than one organism was recovered from 63 catheters and 3 ports. The bacteria and fungi causing the first device-related bacteremia or fungemia are listed in Table 4. The type of organisms causing device-related bacteremia or fungemia differed between catheters and ports, with gram-negative bacilli (55%) isolated predominantly in catheters and gram-positive cocci (65.5%) isolated in ports. Tunnel infection was the initial infection for 17 catheters, but organisms were not isolated in 12 of them. Staphylococcus aureus was the causative organism in two tunnel infections and coagulase-negative staphylococci were the causative organisms in three. A gram-positive bacterium caused each of the 13 port pocket infections: coagulase-negative staphylococci in 1; Streptococcus pneumoniae in 1; diphtheroids in 1; and Staphylococcus aureus in 10. Isolated catheter-site infections without bacteremia or fungemia occurred with 60 catheters. Most catheter site infections were caused by gram-positive cocci, accounting for 61% of episodes. Gram-positive bacilli accounted for 8% of pure site infections, yeast caused 11% of infections, and the remaining 20% were caused by gram-negative bacilli. Twenty-four patients with catheter-related bacteremia or fungemia had an associated site infection. No relation existed between cutaneous cultures and blood isolates because the spectrum of those isolates mimicked those of pure device-related bacteremia or fungemia and site infections. Site infections occurred less frequently in ports than in catheters and were all caused by gram-positive cocci, predominantly coagulase-negative staphylococci.
|
Clinical Outcomes
Twenty-five of 26 ports associated with device-related bacteremia or fungemia as the first infection were sterilized without removal. Subsequently, port pocket infections occurred that required removal of two devices; three devices were further associated with bacteremia but did not require removal. Catheter-related bacteremia or fungemia occurred as the first infection with 264 catheters. One hundred ninety-one catheters were treated successfully and 73 others were removed. Subsequently, a second infection occurred with 83 catheters, and 25 of them were removed. Nineteen catheters were associated with a third or fourth bacteremia, with all devices ultimately removed (10 with the third bacteremia and 9 with the fourth). The organism responsible for the first infection was not predictive of the second organism when repeated infection occurred. One patient died of a catheter-related Klebsiella bacteremia. Sixteen of 17 catheter tunnel infections and 12 of 13 port pocket infections required device removal. Initial site infections occurring in patients with catheters usually responded well to antibiotics, with only 6 of 60 catheters removed. Although 4 of 18 ports were removed for a first site infection, removal of ports for a site infection did not occur statistically more often than removal of catheters. As noted, significantly more catheters (20%) than ports (3%) ultimately were removed for documented infectious morbidity.
Statistical Modeling of Risk Factors for Device-related Infection
Only the first devices inserted in patients who had solid tumors, leukemia, and lymphoma or myeloma were included in the statistical modeling analysis.
Clot occurred in 29 catheters not associated with infection (26 catheter luminal clots, 3 vessel thromboses), in 9 before the first infection (8 catheter luminal clots, 1 vessel thrombosis), and in 16 devices after an infection. Port clots occurred in 17 devices not associated with infection and in 1 port (luminal occlusion) before infection. Forty-three catheters broke and were repaired (19 not associated with infection, 8 repaired before first infection, and 16 repaired after an infection). Neither clot nor repair was related to the probability of device infection.
Our statistical model (with all data) shows a significantly (P < 0.001) higher infection rate in patients who received catheters than in patients who received ports (Table 5). Among patients with solid tumors, young children (<7 years) and young adults (18 to 27 years) had significantly shorter times to infection than did other patients (P = 0.014 and P = 0.04, respectively). However, age was not a significant risk factor for hematopoietic tumors. Among the two hematopoietic groups, patients with leukemia had shorter infection-free times compared with patients with lymphoma or myeloma (P = 0.02). On average, devices inserted in patients with solid tumors had longer infection-free times compared with those in patients with hematologic diseases (P = 0.005). Among patients with hematopoietic diseases, those who were diagnosed with leukemia showed the shortest infection-free times compared with patients with lymphoma or myeloma (P = 0.02).
|
Kaplan-Meier estimates Figure 1 demonstrate graphically the marked differences in infection-free intervals among devices used in patients with the three tumor types and devices.
|
Discussion
|
|---|
|
|
|---|
Infection remains a significant cause of morbidity for patients with venous access devices. Device-related infection can be divided into exit site infection, tunnel tract or port pocket infection, and device-related bacteremia or fungemia. In a review of pediatric patients receiving chemotherapy, children with long-term, right atrial catheters experienced a 6.4 times higher rate of bacteremia and spent an average of 15.4 more days per year in the hospital for treatment-related complications than did a matched population of patients without catheters [29]. The incidence of device-related infection ranges from 2.7% to 60%, depending on the type of device, the criteria used for the diagnosis of device-related infection, and the patient's underlying disease [8, 19, 30-35]. Catheter-related infection occurs frequently in patients with cancer at our medical center, occurring five times more often than port infections, with a 12-fold difference when assessed by incidence of morbidity per device-day. Differences for bacteremia or fungemia are most dramatic, with a 21-fold difference between catheters and ports on a risk-per-day basis. Because the type of device used in the evaluation was not randomly assigned, a bias was introduced; patients with catheters inserted because of their disease process may have their devices accessed more frequently, may have a longer duration of neutropenia, and may require home care. In a small randomized study of 46 adults with hematologic cancers, ports were shown to be as safe as dual-lumen Hickman catheters [7]. Thrombocytopenia with predisposition to hematoma formation after access, frequent phlebotomy, large transfusion requirements, and multiluminal needs for hydration and antibiotics limit the use of dual-lumen ports in patients with hematologic cancers. In a randomized study of infectious morbidity, ports have been shown to be associated with fewer infections than were catheters in patients with solid tumors [8].
The mechanisms of device-related infection may explain why ports are less likely to be associated with infection than are catheters [34]. Migration of skin flora through the cutaneous insertion site with catheter colonization [34, 36] is supported by our finding and that of others that gram-positive organisms, especially coagulase-negative staphylococci, are responsible for a significant percentage of the cases of device-related bacteremia in patients with catheters. Catheter irrigation with solutions containing 25 µg/mL vancomycin may decrease the frequency of bacteremia attributed to luminal colonization with vancomycin-sensitive bacteria [37], but it was not used in our study sample because of the potential for vancomycin-resistant organisms to emerge.
Addition of the Dacron cuff to catheters allows a significantly longer infection-free duration in situ. However, the cuff is not completely protective: Microcolonies of cutaneous bacteria enclosed in a sheath-like glycocalyx matrix adherent to the catheter surface have been seen on removal from patients with cancer [35]. In neutropenic patients, especially in those with altered mucosal barriers, there may be translocation of endogenous gut bacteria to the catheter [38]. Device-related bacteremias at our center support this mechanism because device infections are caused predominantly by gram-negative enteric organisms that occur in patients with leukemia who have catheters. Compared with catheters, ports are irrigated less frequently, require no home care, and are less prone to environmental or cutaneous contamination when not accessed. These factors may also contribute to the decreased incidence of infections associated with ports.
Initial antibiotic therapy for device-related bacteremia or fungemia should be based on knowledge of the patients' host defenses, presence of neutropenia, and type of device. Gram-negative organisms predominate at our medical center in patients with catheter-related bacteremia or fungemia. The experience at our center is that in most instances, catheters associated with bacteremia or fungemia can be sterilized with antibiotics without removal of the device [9, 39]. Specific predictors of treatment success are not available. Development of one catheter-related bacteremia does not always indicate that a second infection will occur, nor does knowledge of the organism of the first infection help the clinician to identify the second organism when repeated infection occurs. Antibiotic sterilization of ports after diagnosis of device-related bacteremia or fungemia also is usually successful without device removal. Ports are most often placed in patients with solid tumors, and coagulase-negative staphylococci are the predominant pathogens. Clinicians should always consider removing any device from patients in whom there is evidence of septic emboli, refractory hypotension, and persistent culture positivity without eradication of infection shown by decreasing serial colony-forming unit counts, and when the device is no longer required for therapy. Our study does not suggest that vessel or catheter thrombosis is a risk factor for infection. The mechanism of catheter tunnel infection remains uncertain because it can occur on a catheter segment on either side of the Dacron cuff and need not be associated with septicemia or with exit site infection. Skin organisms may be transported along the catheter by capillary action at the time of insertion [32]. Our study and that of Benezra and colleagues [9] show that the incidence of tunnel infection is low, accounting for fewer than 2% of all catheter-related infections, occur significantly earlier than device-related bacteremia or fungemia, can be associated with catastrophic local morbidity or death, and invariably require device removal. Addition of a second, more proximal silver-impregnated cuff to Hickman catheters does not alter the incidence of bacteremias, and because the incidence of tunnel infection is low, a large, multicenter study is needed to prove efficacy against tunnel infection [40]. Port pocket infections, usually caused by gram-positive cocci, suggest direct inoculation or migration of organisms along the accessing needle as the primary mechanism. Regardless of the underlying disease, all port pocket infections have been caused by Staphylococcus aureus and require removal.
Site infection can range from a small infection easily managed with local care and topical antibiotics to a more aggressive type of infection with progression to cellulitis, tunnel or pocket infection, or septicemia. Evidence of erythema and exudate may be subtle in the neutropenic, immunosuppressed patient. If possible, patients with port site infections should have the Huber point needle removed, and an intravenous access remote from the site should be established for delivery of antibiotic agents until all signs of site infection resolve.
For all categories of infection, risk is greater in patients with catheters compared with ports. At our center, implanted ports are used whenever possible. A randomized trial of ports compared with catheters in patients with similar infusion, transfusion, phlebotomy, and device-accessing requirements and on treatment regimens associated with similar degrees and duration of neutropenia still is needed to distinguish the influences of disease and therapy from specific devices with regard to infectious morbidity.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Wurzel CL, Halom K, Feldman JG, Rubin LG. Infection rates of Broviac-Hickman catheters and implantable venous devices. Am J Dis Child. 1988; 142:536-40.
2. Johnson PR, Decker MD, Edwards KM, Schaffner W, Wright PF. Frequency of Broviac catheter infection in pediatric oncology patients. J Infect Dis. 1986; 154:570-8.
3. Ingram J, Weitzman S, Greenberg ML, Parkin P, Filler R. Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports. Am J Pediatr Hematol Oncol. 1991; 13: 130-6.
4. Dawson S, Pai MK, Smith S, Rothney M, Ahmed K, Barr RD. Right atrial catheters in children with cancer: a decade of experience in the use of tunnelled, exteriorized devices at a single institution. Am J Pediatr Hematol Oncol. 1991; 13:126-9.
5. Moosa HH, Julian TB, Rosenfeld CS, Shadduck RK. Complications of indwelling central venous catheters in bone marrow transplant recipients. Surg Gynecol Obstet. 1991; 172:275-9.
6. Kiehn TE, Armstrong D. Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices. Eur J Clin Microbiol Infect Dis. 1990; 9:869-2.
7. Kappers Klunne MC, Degener JE, Stijnen T, Abels J. Complications from long-term indwelling central venous catheters in hematologic patients with special reference to infection. Cancer. 1989; 64:1747-52.[Medline]
8. Carde P, Cosset Delaigue MF, Laplanche A, Chareau I. Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors. Eur J Cancer Clin Oncol. 1989; 25:939-44.
9. Benezra D, Kiehn TE, Gold JW, Brown AE, Turnbull AD, Armstrong D. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am J Med. 1988; 85:495-8.
10. Wurzel CL, Halom K, Feldman JG, Rubin LG. Infection rates of Broviac-Hickman catheters and implantable venous devices. Am J Dis Child. 1988; 142:536-40.
11. Jacobs MB, Yeager M. Thrombotic and infectious complications of Hickman-Broviac catheters. Arch Int Med. 1984; 144:1597-9.
12. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine. 1984; 63:189-200.
13. Brothers TE, Von Moll LK, Niederhuber JE, Roberts JA, Walker-Andrews S, Ensminger WD. Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet. 1988; 166:295-301.
14. Wesenberg F, Anker C, Sommerschild H, Flaatten H. Central venous catheter with subcutaneous injection port (Port-A-Cath): clinical experience with children. Pediatr Hematol Oncol. 1987; 4:137-43.
15. Grannan KJ, Taylor PH. Early and late complications of totally implantable venous access devices. J Surg Oncol. 1990; 44:52-4.
16. Mirro J Jr, Rao BN, Kumar M, Rafferty M, Hancock M, Austin BA, et al. A comparison of placement techniques and complications of externalized catheters and implantable port use in children with cancer. J Pediatr Surg. 1990; 25:120-4.[Medline]
17. Brincker H, Saeter G. Fifty-five patient years' experience with a totally implanted system for intravenous chemotherapy. Cancer. 1986; 57:1124-9.
18. Lokich JJ, Bothe A Jr, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol. 1985; 3:710-17.
19. Whimbey E, Wong B, Kiehn TE, Armstrong D. Clinical correlations of serial quantitative blood cultures determined by lysis-centrifugation in patients with persistent septicemia. J Clin Microbiol. 1984; 19:766-71.
20. Broviac JW, Scribner BH. Prolonged parenteral nutrition in the home. Surg Gynecol Obstet. 1974; 139:24-8.
21. Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet. 1979; 148:871-5.
22. Riella MC, Scribner BH. Five years' experience with a right atrial catheter for prolonged parenteral nutrition at home. Surg Gynecol Obstet. 1976; 143:205-8.
23. Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery. 1982; 92: 706-12.
24. Mirro J Jr, Rao BN, Stokes DC, Austin BA, Kumar M, Dahl GV, et al. A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. J Clin Oncol. 1989; 7:214-22.[Abstract]
25. Hockenberry MJ, Schultz WH, Bennett B, Bryant R, Falletta JM. Experience with minimal complications in implanted catheters in children. Am J Pediatr Hematol Oncol. 1989; 11:295-9.
26. Ross MN, Haase GM, Poole MA, Burrington JD, Odom LF. Comparison of totally implanted reservoirs with external catheters as venous access devices in pediatric oncologic patients. Surg Gynecol Obstet. 1988; 167:141-4.
27. Shulman RJ, Rahman S, Mahoney D, Pokorny WJ, Bloss R. A totally implanted venous access system used in pediatric patients with cancer. J Clin Oncol. 1987; 5:137-40.
28. Strum S, McDermed J, Korn A, Joseph C. Improved methods for venous access: the Port-A-Cath, a totally implanted catheter system. J Clin Oncol. 1986; 4:596-603.
29. Van Hoff J, Berg AT, Seashore JH. The effect of right atrial catheters on infectious complications of chemotherapy in children. J Clin Oncol. 1990; 8:1255-62.[Abstract]
30. Andremont A, Paulet R, Nitenberg G, Hill C. Value of semiquantitative cultures of blood drawn through catheter hubs for estimating the risk of catheter tip colonization in cancer patients. J Clin Microbiol. 1988; 26:2297-9.
31. Brun-Buisson C, Abrouk F, Legrand P, Huet Y, Larabi S, Rapin M. Diagnosis of central venous catheter-related sepsis. Arch Intern Med. 1987; 147:873-7.
32. Cooper GL, Schiller A, Hopkins CC. Possible role of capillary action in pathogenesis of experimental catheter-associated dermal tunnel infections. J Clin Microbiol. 1988; 26:8-12.
33. Cooper GL, Hopkins CC. Rapid diagnosis of intravascular catheter-associated infection by direct Gram staining of catheter segments. N Engl J Med. 1985; 312:1142-7.
34. Maki DG. Infections associated with intravascular lines. In: Swartz M, Remmington J, eds. Current Topics in Clinical Infectious Disease. New York: McGraw-Hill; 1982:309.
35. Tenney JH, Moody MR, Newman KA, Schimpff SC, Wade JC, Costerton JW, et al. Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Arch Intern Med. 1986; 146: 1949-54.
36. Maki DG, Cobb L, Garman JK, Shapiro JM, Ringer M, Helgerson RB. An attachable silver-impregnanted cuff for prevention of infection with central venous catheters: A prospective randomized multicenter trial. Am J Med. 1988; 85:307-14.
37. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990; 8:1591-7.
38. Tancrede CH, Andremont AO. Bacterial translocation and gram negative bacteremia in patients having hematological malignancies. J Infect Dis. 1985; 15:99-103.
39. Flynn PM, Shenep JL, Stokes DC, Barrett FF. In situ management of confirmed central venous catheter-related bacteremia. Pediatr Infect Dis J. 1987; 6:729-34.
40. Groeger JS, Lucas AB, Coit D, La Quaglia M, Brown AE, Turnbull A, et al. A prospective randomized evaluation of silver impregnated subcutaneous cuffs for preventing tunneled chronic venous access catheter infections in cancer patients. Ann Surg. 1993; 218:206-10.
This article has been cited by other articles:
![]() |
M. E. Falagas, K. Fragoulis, I. A. Bliziotis, and I. Chatzinikolaou Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials J. Antimicrob. Chemother., March 1, 2007; 59(3): 359 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hanna, R. Benjamin, I. Chatzinikolaou, B. Alakech, D. Richardson, P. Mansfield, T. Dvorak, M. F. Munsell, R. Darouiche, H. Kantarjian, et al. Long-Term Silicone Central Venous Catheters Impregnated With Minocycline and Rifampin Decrease Rates of Catheter-Related Bloodstream Infection in Cancer Patients: A Prospective Randomized Clinical Trial J. Clin. Oncol., August 1, 2004; 22(15): 3163 - 3171. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Dillon, G. R. Jones, H. A. Bagnall-Reeb, J. D. Buckley, E. S. Wiener, and G. M. Haase Prophylactic Urokinase in the Management of Long-Term Venous Access Devices in Children: A Children's Oncology Group Study J. Clin. Oncol., July 1, 2004; 22(13): 2718 - 2723. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Biffi, S. Pozzi, A. Agazzi, U. Pace, A. Floridi, S. Cenciarelli, V. Peveri, A. Cocquio, B. Andreoni, and G. Martinelli Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients Ann. Onc., February 1, 2004; 15(2): 296 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Verso and G. Agnelli Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients J. Clin. Oncol., October 1, 2003; 21(19): 3665 - 3675. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. W. Klerk, S. M. Smorenburg, and H. R. Buller Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review Arch Intern Med, September 8, 2003; 163(16): 1913 - 1921. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Seifert, O. Cornely, K. Seggewiss, M. Decker, D. Stefanik, H. Wisplinghoff, and G. Fatkenheuer Bloodstream Infection in Neutropenic Cancer Patients Related to Short-Term Nontunnelled Catheters Determined by Quantitative Blood Cultures, Differential Time to Positivity, and Molecular Epidemiological Typing with Pulsed-Field Gel Electrophoresis J. Clin. Microbiol., January 1, 2003; 41(1): 118 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. P. O'Grady, M. Alexander, E. P. Dellinger, J. L. Gerberding, S. O. Heard, D. G. Maki, H. Masur, R. D. McCormick, L. A. Mermel, M. L. Pearson, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections Pediatrics, November 1, 2002; 110(5): e51 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. McNelis, J. Zarcone, and A. Jurkiewicz Outcome of Subcutaneously Implanted Catheters in a Teaching Hospital American Journal of Medical Quality, September 1, 2002; 17(5): 185 - 188. [Abstract] [PDF] |
||||
![]() |
C. Arpin, V. Dubois, A.-M. Rogues, F. Menard, A.-M. Gavinet, J.-P. Maire, J.-P. Gachie, M.-C. Bezian, and C. Quentin Cross-Infection Due to Imipenem-Resistant Bacteroides fragilis Associated with a Totally Implantable Venous Port J. Clin. Microbiol., August 1, 2002; 40(8): 3032 - 3034. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Walshe, S. F. Malak, J. Eagan, and K. A. Sepkowitz Complication Rates Among Cancer Patients With Peripherally Inserted Central Catheters J. Clin. Oncol., August 1, 2002; 20(15): 3276 - 3281. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Funaki Central Venous Access: A Primer for the Diagnostic Radiologist Am. J. Roentgenol., August 1, 2002; 179(2): 309 - 318. [Full Text] [PDF] |
||||
![]() |
E. NICASTRI, N. PETROSILLO, P. VIALE, and G. IPPOLITO Catheter-Related Bloodstream Infections in HIV-Infected Patients Ann. N.Y. Acad. Sci., November 1, 2001; 946(1): 274 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Marconi, I. Francolini, A. Piozzi, and R. D. Rosa Antibiotic Releasing Urethane Polymers for Prevention of Catheter Related Infections Journal of Bioactive and Compatible Polymers, September 1, 2001; 16(5): 393 - 407. [Abstract] [PDF] |
||||
![]() |
Y. Haimi-Cohen, N. Husain, J. Meenan, G. Karayalcin, M. Lehrer, and L. G. Rubin Vancomycin and Ceftazidime Bioactivities Persist for at Least 2 Weeks in the Lumen in Ports: Simplifying Treatment of Port-Associated Bloodstream Infections by Using the Antibiotic Lock Technique Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1565 - 1567. [Abstract] [Full Text] |
||||
![]() |
D. Kuizon, S. M. Gordon, and B. L. Dolmatch Single-Lumen Subcutaneous Ports Inserted by Interventional Radiologists in Patients Undergoing Chemotherapy: Incidence of Infection and Outcome of Attempted Catheter Salvage Arch Intern Med, February 12, 2001; 161(3): 406 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. B. Malgrange, M. C. Escande, and S. Theobald Validity of Earlier Positivity of Central Venous Blood Cultures in Comparison with Peripheral Blood Cultures for Diagnosing Catheter-Related Bacteremia in Cancer Patients J. Clin. Microbiol., January 1, 2001; 39(1): 274 - 278. [Abstract] [Full Text] |
||||
![]() |
G. R. Donowitz, D. G. Maki, C. J. Crnich, P. G. Pappas, and K. V.I. Rolston Infections in the Neutropenic Patient-- New Views of an Old Problem Hematology, January 1, 2001; 2001(1): 113 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. O. Trerotola Hemodialysis Catheter Placement and Management Radiology, June 1, 2000; 215(3): 651 - 658. [Abstract] [Full Text] |
||||
![]() |
S. S. Dhillon and C. Watanakunakorn Pneumococcal Bacteremia Associated With an Infected Central Venous Catheter Chest, May 1, 2000; 117(5): 1515 - 1516. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Tokars, S. T. Cookson, M. A. McArthur, C. L. Boyer, A. J. McGeer, and W. R. Jarvis Prospective Evaluation of Risk Factors for Bloodstream Infection in Patients Receiving Home Infusion Therapy Ann Intern Med, September 7, 1999; 131(5): 340 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Carratalà, J. Niubó, A. Fernández-Sevilla, E. Juvé, X. Castellsagué, J. Berlanga, J. Liñares, and F. Gudiol Randomized, Double-Blind Trial of an Antibiotic-Lock Technique for Prevention of Gram-Positive Central Venous Catheter-Related Infection in Neutropenic Patients with Cancer Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2200 - 2204. [Abstract] [Full Text] |
||||
![]() |
T. U. Anthony and L. G. Rubin Stability of Antibiotics Used for Antibiotic-Lock Treatment of Infections of Implantable Venous Devices (Ports) Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2074 - 2076. [Abstract] [Full Text] |
||||
![]() |
F. Krug, D. Psathakis, U. Hirsch, and H.-P. Bruch The K-port concept: Proposal for optimising a fully implantable port system Journal of Oncology Pharmacy Practice, June 1, 1999; 5(2): 67 - 74. [Abstract] [PDF] |
||||
![]() |
E. J. Bow, M. G. Kilpatrick, and J. J. Clinch Totally Implantable Venous Access Ports Systems for Patients Receiving Chemotherapy for Solid Tissue Malignancies: A Randomized Controlled Clinical Trial Examining the Safety, Efficacy, Costs, and Impact on Quality of Life J. Clin. Oncol., April 1, 1999; 17(4): 1267 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
|